# Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

> **NCT00232479** · PHASE2 · COMPLETED · sponsor: **University of Miami** · enrollment: 48 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** trastuzumab, docetaxel and carboplatin in dose dense regimen

## Key facts

- **NCT ID:** NCT00232479
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-05
- **Final completion:** 2008-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00232479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00232479, "Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00232479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*